Cantor Fitzgerald Initiates Coverage On Krystal Biotech with Overweight Rating, Announces Price Target of $160
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has initiated coverage on Krystal Biotech (NASDAQ:KRYS) with an Overweight rating and a price target of $160.
October 24, 2023 | 8:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech has been given an Overweight rating and a price target of $160 by Cantor Fitzgerald.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Krystal Biotech. The price target of $160 suggests significant upside potential from the current price. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100